Cardiovascular risk reduction strategies in community pharmacy settings need real world angle

Canadian Pharmacists Journal

Volumn 140, Issue 5, 2007, Pages 295-297

  Blackburn, David F ^a   Evans, Charity ^a   Lamb, Darcy A ^a   Taylor, Jeffrey G ^a   Skilton, Kevin ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR RISK; HEALTH CARE SYSTEM; HUMAN; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACY; POINT OF CARE TESTING; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK REDUCTION; SHORT SURVEY;

EID: 34848828571     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.3821/1913-701X(2007)140[295:CRRSIC]2.0.CO;2     Document Type: Short Survey

References (17)

1. Health Quality Council. Many Saskatchewan heart attack patients not on key life-saving medications. Available: www.hqc.sk.ca/portal.jsp?PAwKMZBBBZ9/ FpVJuVtIZT-BIzBf0QfLQkUwK4QBZaJv/lsFHkVd8LCt1ssWtuDunjM5Vw D6WZjg= (accessed August 13, 2007).
2. Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers, and angiotensin converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21:485-8.
3. Tsuyuki RT, Semchuk W, Poirier L, et al. 2006 Canadian Hypertension Education Program guidelines for the management of hypertension by pharmacists. Can Pharm J 2006;139[Suppl 1]:S11-S13.
4. Wiedenmayer K, Summers RS, Mackie CA, et al. Developing pharmacy practice: a focus on patient care. Handbook, 2006 ed. World Health Organization and International Pharmaceutical Federation. Available: www.who.int/medicines/ publications/ WHO_PSM_PAR_2006.5.pdf (accessed June 27, 2006).
5. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. A randomized controlled trial. JAMA 2006;296:2563-71.
6. Wu JYF, Leung WYS, Chang S, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomized controlled trial. BMJ 2006;333:522-7.
7. Ali F, Laurin M-Y, Larieviere C, et al. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003;10:101-6.
8. Chabot I, Moisan J, Gregoire JP, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother 2003;37(9):1186-93.
9. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
10. Semchuk W, Taylor J, Sulz L, et al. Pharmacist Intervention in Risk Reduction study: high-risk cardiac patients. Can Pharm J 2007;140:32-7.
11. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
12. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
13. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
14. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279: 1458-62.
15. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10(10):1097-102.
16. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003;289:305-12.
17. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.